QUCY · Quantum Cyber N.V.
The latest filing states the doubt was alleviated.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management evaluated conditions and events that raise substantial doubt and the Company's plans to mitigate those conditions over the one-year look-forward period from the date these consolidated financial statements are issued. The Company believes that its currently available cash on hand, together with additional financing described above, will be sufficient to meet its planned expenditures and obligations for at least the one-year period following the issuance of its consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-11 | Caragol William J |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
212,500 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↓
Filing footnotes — Series B Preferred Shares (Direct)
Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. Each class of Preferred Shares is perpetual and therefore has no expiration date. |
Series B Preferred Shares
|
1,000,000 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↓
Filing footnotes — Series A Preferred Shares (Direct)
Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. Each class of Preferred Shares is perpetual and therefore has no expiration date. |
Series A Preferred Shares
|
1,000,000 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↑
|
Ordinary Shares
|
9,000,000 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↑
|
Ordinary Shares
|
9,000,000 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↑
|
Ordinary Shares
|
28,057,500 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↓
Filing footnotes — Series D Preferred Shares (Direct)
Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. Each class of Preferred Shares is perpetual and therefore has no expiration date. |
Series D Preferred Shares
|
124,700 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↑
|
Ordinary Shares
|
9,000,000 |
| 2026-08-05 | Lazar David E. |
10% Owner |
Other↓
Filing footnotes — Series C Preferred Shares (Direct)
Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. Each class of Preferred Shares is perpetual and therefore has no expiration date. |
Series C Preferred Shares
|
1,000,000 |
| 2026-07-22 | O'Rourke Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
191,860 |
| 2026-07-22 | NATAN DAVID |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
191,860 |
| 2026-07-22 | Ben-Tzvi Avraham |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. |
Ordinary Shares
|
112,859 |
| 2026-07-22 | Buffalino Louis R. |
Director, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The purpose of this Form 4/A is to correct the date of the reported transaction. The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
425,000 |
| 2026-07-22 | Caragol William J |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The purpose of this Form 4/A is to correct the date of the reported transaction. The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
212,500 |
| 2026-07-06 | O'Rourke Peter |
Director |
Award↑
|
Stock Option (Right to Buy)
|
112,859 |
| 2026-05-08 | NATAN DAVID |
Director |
Award↑
|
Ordinary Shares
|
137,141 |
| 2026-05-08 | Ben-Tzvi Avraham |
Director |
Award↑
|
Ordinary Shares
|
137,141 |
| 2026-04-22 | Lazar David E. |
10% Owner |
Award↑
Filing footnotes — Series D Preferred Shares (Direct)
As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. |
Series D Preferred Shares
|
1,000,000 |
| 2026-04-22 | Lazar David E. |
10% Owner |
Award↑
Filing footnotes — Series E Preferred Shares (Direct)
As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. |
Series E Preferred Shares
|
1,000,000 |
| 2026-02-13 | Lazar David E. |
10% Owner |
Award↑
Filing footnotes — Series B Preferred Shares (Direct)
On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. |
Series B Preferred Shares
|
1,000,000 |
| 2026-02-13 | Lazar David E. |
10% Owner |
Award↑
Filing footnotes — Series A Preferred Shares (Direct)
On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. |
Series A Preferred Shares
|
1,000,000 |
| 2026-02-13 | Caragol William J |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 77,899 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. |
Ordinary Shares
|
290,000 |
| 2026-02-13 | Dreismann Heinrich |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. |
Ordinary Shares
|
45,000 |
| 2026-02-13 | Lazar David E. |
10% Owner |
Award↑
Filing footnotes — Series C Preferred Shares (Direct)
On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. |
Series C Preferred Shares
|
1,000,000 |
| 2026-02-13 | Tibbitts Gregory J |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 10,875 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. |
Ordinary Shares
|
45,000 |
| 2026-02-13 | BAECHLER GUIDO |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 6,362 ordinary shares held, and 158,696 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. |
Ordinary Shares
|
440,000 |
| 2025-10-17 | Donahue Kevin Michael |
10% Owner |
Buy↑
|
Common Stock
|
643,850 |
| 2025-10-17 | Donahue Kevin Michael |
10% Owner |
Buy↑
|
Common Stock
|
685,000 |